Results 91 to 100 of about 21,815 (182)
Androgen Receptor (AR) signaling is a critical driver of hormone-dependent prostate cancer and has also been proposed to have biological activity in female hormone-dependent cancers, including type I endometrial carcinoma (EMC).
Christopher S. Koivisto +14 more
doaj +1 more source
Jia Luo,1 Julie N Graff2,3 1Department of Medicine; 2Knight Cancer Institute, Oregon Health & Science University, 3VA Portland Health Care System, Portland, OR, USA Abstract: Prostate cancer claims the lives of more than 25,000 men in the United
Graff JN, Luo J
core
Background Abiraterone and enzalutamide are widely used androgen receptor pathway inhibitors (ARPIs) for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), but the optimal initial treatment strategy remains uncertain ...
Jin Bong Choi, Yun-Hee Lee, U-Syn Ha
doaj +1 more source
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li +21 more
wiley +1 more source
TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
Background Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms.
Louie Semaan +3 more
doaj +1 more source
Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang +4 more
wiley +1 more source
Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo +8 more
wiley +1 more source
Antioxidant Programs Are Essential for Enzalutamide-Resistant Prostate Cancer [PDF]
Therapy resistance to second generation androgen receptor (AR) antagonists, such as enzalutamide, is common in patients with advanced prostate cancer (PCa).
Blatt, Eliot Benjamin
core +1 more source
Background: Enzalutamide, approved in China for the treatment of prostate cancer (PC), has been studied for risk of seizure, but there is limited real-world evidence on this risk in China.
Yong Wang +13 more
doaj +1 more source
Objective: To review the efficacy and safety of reduced dose compared to standard dose Enzalutamide treatment for patients with castration-resistant prostate cancer (CRPC). Methods: PubMed, Scopus, Web of Science, and Cochrane databases were searched for
Zineddine Belabaci +11 more
doaj +1 more source

